5mg Semaglutide Peptide: Separating Fact from Fiction

The myth worth clearing up first: 5mg semaglutide as a "peptide" is not a licensed treatment

The phrase "5mg semaglutide peptide" circulates widely on fitness forums and through social-media sellers. The idea (that you can source a raw or compounded peptide form of semaglutide outside the pharmacy system) is one our clinical team encounters regularly. It's worth understanding gently, without alarm, because most people searching for it aren't trying to do anything reckless; they've simply read misleading content and want to know what's actually out there.

Semaglutide is indeed a peptide by molecular classification. But in UK law, it is a prescription-only medicine regardless of how it's described or packaged. Compounded or "research grade" semaglutide sold online (often at lower prices, often with doses like 5mg or 10mg that don't correspond to any licensed schedule) has not been assessed for quality, potency or sterility by the MHRA. Potency in unlicensed compounded products can vary enormously, which means a stated 5mg dose tells you very little about what you'd actually be injecting. The MHRA's Yellow Card reporting system has received reports linked to such products, and enforcement operations have seized large quantities of fake weight-loss pens from the UK supply chain.

If you're considering semaglutide for weight management, the licensed route is the relevant one, and it starts with a clinical assessment, not a checkout basket.

What 5mg might actually mean in a semaglutide context

For readers who arrived here wondering whether there's a 5mg dose step in the licensed Wegovy programme, the straightforward answer is no. The UK-approved titration schedule for the Wegovy injection runs from 0.25mg through to a 2.4mg maintenance dose. A newer 7.2mg maintenance dose was approved by the MHRA on 14 April 2026 for adults with a BMI of 30 or above, delivered via a dedicated single-dose pen. There is no 5mg rung in any part of that ladder.

The 5mg figure appears more frequently in the context of oral semaglutide, though again not as a licensed dose step. The Wegovy tablet (approved by the MHRA on 11 June 2026 as the UK's first oral GLP-1 medicine for weight management) follows a schedule of 1.5mg, 4mg, 9mg and 25mg. The full breakdown of licensed semaglutide doses explains each step in the titration pathway and what the prescriber is aiming for at each stage. Anyone who has read about a 5mg tablet in a weight-loss context has likely encountered information about Rybelsus, which is oral semaglutide at 3mg, 7mg and 14mg, but Rybelsus is licensed for type 2 diabetes, not weight management. The two products are not interchangeable.

For context on how Wegovy's various dose formats are structured and what's available privately in the UK, the guide to Wegovy dose options is a useful next step.

Why dose and formulation matter more than the number on the label

One thing that tends to get lost in online discussions about semaglutide is that the dose number alone is not the meaningful variable. What matters is whether the product is genuine, whether it has been manufactured to the quality standards required of a licensed medicine, and whether a prescriber has assessed whether it's appropriate for you at that specific strength at that specific point in your treatment.

The licensed Wegovy titration schedule starts low for a reason: the slower the ascent, the better most people tolerate the gastrointestinal side effects (nausea, reflux, changes in bowel habit) that are common in the early weeks. A prescriber decides when to move up based on how your body is responding, not on a fixed calendar. That clinical judgement is absent when someone self-sources a product online, at a dose that isn't derived from any evidence base.

The trial evidence that underpins Wegovy's licensing comes from the STEP programme, including the STEP 1 trial published in the New England Journal of Medicine, which found an average body-weight reduction of around 15% over 68 weeks at the 2.4mg dose. Those results were generated in a controlled setting with genuine licensed medicine at calibrated doses, not with compounded alternatives at arbitrary strengths. If you have come across references to 10 mg semaglutide peptide, our dedicated page explains why that description sits outside the licensed framework and what it actually refers to.

If you want to understand how costs for the licensed treatment compare across dose levels, the Wegovy cost guide sets out what private treatment actually involves and what the price reflects.

The safe route to semaglutide for weight management in the UK

The NHS medicines guidance on semaglutide is clear: this is a prescription-only medicine, and any supply without a valid prescription is unlawful. The MHRA licenses semaglutide for weight management only in the form of Wegovy, the injection and (from June 2026) the tablet. Unlicensed compounded versions, including anything described as a "semaglutide peptide" at doses like 5mg, fall outside that framework entirely.

Through a GPhC-registered online pharmacy like nume, the process runs like this: a free consultation, a same-day clinical review by a GPhC-registered Independent Prescriber, identity and weight verification, and once approved, same-day dispatch with free next-working-day tracked delivery. You can verify any online pharmacy on the GPhC register before you proceed, for reference, our registration number is 9012878.

Red flags that should give you pause: sellers offering semaglutide without a consultation, products described as "peptides" or "research chemicals", pricing well below the market rate, and anything sold via social media without pharmacy verification, including devices marketed as the Viogen semaglutide 10mg pen, which is not a licensed medicine and falls into exactly the category of unverified supply our clinical team advises against. A small saving is not the right trade-off for a medicine that needs prescriber oversight to be used safely.

If you'd like to explore whether licensed semaglutide treatment is suitable for you, our prescribers are the right place to start. Speak to our prescribers through a free consultation, no commitment, no subscription, just a genuine clinical conversation.